TY - JOUR
T1 - Use of exploratory factor analysis to ascertain the correlation between the activities of rheumatoid arthritis and infection by human parvovirus B19
AU - Kakurina, Natalja
AU - Kadisa, Anda
AU - Lejnieks, Aivars
AU - Mikazane, Helena
AU - Kozireva, Svetlana
AU - Murovska, Modra
N1 - Funding Information:
This study was supported in part by the grant 09.1112 of the Latvian Council of Sciences and National Program in Biomedicine (2009–2013).
Publisher Copyright:
© 2015 Lithuanian University of Health Sciences.
Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 2015
Y1 - 2015
N2 - Background and objective: We evaluated a possible correlation between the clinical activities of rheumatoid arthritis (RA) and human parvovirus B19 (B19) infection using exploratory factor analysis (EFA). Materials and methods: RA patients were organized into two groups: 100 patients in the main group and 97 in the RA(DAS28) group. Four subgroups were defined from the main group according to the presence or absence of certain infection-specific markers: group I comprised 43 patients who had IgG antibodies against B19; group II, 25 patients with active B19 infection (B19-specific IgM antibodies and/or plasma viremia); group III, 19 patients with latent/persistent B19 infection (virus-specific sequences in peripheral blood leukocytes' DNA with or without B19-specific IgG antibodies), and group IV, 13 patients without infection markers. The RA(DAS28) group was divided into four subgroups similarly to the main group: group I, 35; group II, 31; group III, 19; and group IV, 12 patients. Disease-specific clinical values in both groups were analyzed employing EFA, and the RA(DAS28) group was additionally assessed using Disease Activity Score (DAS)28. Results: RA activity was higher in patients who had markers of B19 infection. The highest activity of RA in both study groups was in patients with latent/persistent infection. In the RA(DAS28) group, according to DAS28, the highest activity of RA was in patients with active B19 infection. Conclusions: Using EFA and DAS28, a correlation between the clinical activity of RA and B19 infection was confirmed. These data suggest that EFA is applicable for medico-biological studies.
AB - Background and objective: We evaluated a possible correlation between the clinical activities of rheumatoid arthritis (RA) and human parvovirus B19 (B19) infection using exploratory factor analysis (EFA). Materials and methods: RA patients were organized into two groups: 100 patients in the main group and 97 in the RA(DAS28) group. Four subgroups were defined from the main group according to the presence or absence of certain infection-specific markers: group I comprised 43 patients who had IgG antibodies against B19; group II, 25 patients with active B19 infection (B19-specific IgM antibodies and/or plasma viremia); group III, 19 patients with latent/persistent B19 infection (virus-specific sequences in peripheral blood leukocytes' DNA with or without B19-specific IgG antibodies), and group IV, 13 patients without infection markers. The RA(DAS28) group was divided into four subgroups similarly to the main group: group I, 35; group II, 31; group III, 19; and group IV, 12 patients. Disease-specific clinical values in both groups were analyzed employing EFA, and the RA(DAS28) group was additionally assessed using Disease Activity Score (DAS)28. Results: RA activity was higher in patients who had markers of B19 infection. The highest activity of RA in both study groups was in patients with latent/persistent infection. In the RA(DAS28) group, according to DAS28, the highest activity of RA was in patients with active B19 infection. Conclusions: Using EFA and DAS28, a correlation between the clinical activity of RA and B19 infection was confirmed. These data suggest that EFA is applicable for medico-biological studies.
KW - Exploratory factor analysis
KW - Human parvovirus B19
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=84951977658&partnerID=8YFLogxK
U2 - 10.1016/j.medici.2015.01.004
DO - 10.1016/j.medici.2015.01.004
M3 - Article
C2 - 25744771
AN - SCOPUS:84951977658
SN - 1010-660X
VL - 51
SP - 18
EP - 24
JO - Medicina (Lithuania)
JF - Medicina (Lithuania)
IS - 1
ER -